{"pmid":32348046,"title":"[Rheumatology and COVID-19].","text":["[Rheumatology and COVID-19].","Current pandemic implies changes in patient care in rheumatology to reduce the risk of coronavirus transmission to patients visiting health-care facilities, by organizing less frequent blood tests, using teleconsultations, and switching from intravenous to subcutaneous drug administration. Patients under immunosuppressive treatment are considered at high risk of severe outcome and are protected accordingly by the Swiss authorities. However, current, scarce scientific evidence suggests that patients under immunosuppressive therapy do not necessarily develop severe COVID-19 presentations. Therefore, the current guidelines recommend pursuing the treatment throughout the pandemic. In case of SARS-CoV-2 infection, immunosuppressive drugs should be temporarily stopped, except for glucocorticoids, hydroxychloroquine and sulfasalazine.","Rev Med Suisse","Dumusc, Alexandre","Dan, Diana","32348046"],"abstract":["Current pandemic implies changes in patient care in rheumatology to reduce the risk of coronavirus transmission to patients visiting health-care facilities, by organizing less frequent blood tests, using teleconsultations, and switching from intravenous to subcutaneous drug administration. Patients under immunosuppressive treatment are considered at high risk of severe outcome and are protected accordingly by the Swiss authorities. However, current, scarce scientific evidence suggests that patients under immunosuppressive therapy do not necessarily develop severe COVID-19 presentations. Therefore, the current guidelines recommend pursuing the treatment throughout the pandemic. In case of SARS-CoV-2 infection, immunosuppressive drugs should be temporarily stopped, except for glucocorticoids, hydroxychloroquine and sulfasalazine."],"journal":"Rev Med Suisse","authors":["Dumusc, Alexandre","Dan, Diana"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348046","source":"PubMed","week":"202018|Apr 27 - May 03","locations":["Swiss"],"countries":["Switzerland"],"countries_codes":["CHE|Switzerland"],"e_drugs":["Hydroxychloroquine","Sulfasalazine"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1665441658242596865,"score":8.599203,"similar":[{"pmid":32277367,"title":"Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","text":["Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.","Clin Rheumatol","Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena","32277367"],"abstract":["The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice."],"journal":"Clin Rheumatol","authors":["Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277367","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10067-020-05073-9","keywords":["covid-19","epidemiology","hydroxychloroquine","hypothesis","immunity","pathogenesis","vaccines","vitamin d"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["thrombocytopenia","Cytokine","myocarditis","leucopenia","lymphopenia","thrombocytopenia"],"e_drugs":["Ibuprofen","tocilizumab","remdesivir","lopinavir-ritonavir drug combination","favipiravir","Chloroquine","Hydroxychloroquine"],"_version_":1664636943925772288,"score":235.75378},{"pmid":32304488,"title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.","text":["Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.","BACKGROUND: COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. METHODS: This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. RESULTS: Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. CONCLUSIONS: With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.","Ther Drug Monit","Elens, Laure","Langman, Loralie J","Hesselink, Dennis A","Bergan, Stein","Moes, Dirk Jan A R","Molinaro, Mariadelfina","Venkataramanan, Raman","Lemaitre, Florian","32304488"],"abstract":["BACKGROUND: COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. METHODS: This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. RESULTS: Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. CONCLUSIONS: With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided."],"journal":"Ther Drug Monit","authors":["Elens, Laure","Langman, Loralie J","Hesselink, Dennis A","Bergan, Stein","Moes, Dirk Jan A R","Molinaro, Mariadelfina","Venkataramanan, Raman","Lemaitre, Florian"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304488","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FTD.0000000000000761","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664632934598967296,"score":220.51096},{"pmid":32339304,"title":"Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.","text":["Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.","Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome virus (SARS-CoV-2) has become a global healthcare crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high-risk for severe disease from SARS-CoV-2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression, however, there are no current guidelines recommending the optimal approach to managing immunosuppression in the patients who are infected with SARS-CoV-2. It is currently recommended to avoid corticosteroids in the treatment of SARS-CoV-2 outside of critically ill patients. Recently published cases describing the inpatient care of COVID-19 in renal transplant recipients differ widely in disease severity, time from transplantation, baseline immunosuppressive therapy, and the modifications made to immunosuppression during COVID-19 treatment. The purpose of this review is to summarize and compare inpatient immunosuppressant management strategies of recently published reports in the renal transplant population infected with SARS-CoV-2 and to discuss the limitations of corticosteroids in managing immunosuppression in this patient population.","Pharmacotherapy","Johnson, Kristen M","Belfer, Julie J","Peterson, Gina R","Boelkins, Mark R","Dumkow, Lisa E","32339304"],"abstract":["Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome virus (SARS-CoV-2) has become a global healthcare crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high-risk for severe disease from SARS-CoV-2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression, however, there are no current guidelines recommending the optimal approach to managing immunosuppression in the patients who are infected with SARS-CoV-2. It is currently recommended to avoid corticosteroids in the treatment of SARS-CoV-2 outside of critically ill patients. Recently published cases describing the inpatient care of COVID-19 in renal transplant recipients differ widely in disease severity, time from transplantation, baseline immunosuppressive therapy, and the modifications made to immunosuppression during COVID-19 treatment. The purpose of this review is to summarize and compare inpatient immunosuppressant management strategies of recently published reports in the renal transplant population infected with SARS-CoV-2 and to discuss the limitations of corticosteroids in managing immunosuppression in this patient population."],"journal":"Pharmacotherapy","authors":["Johnson, Kristen M","Belfer, Julie J","Peterson, Gina R","Boelkins, Mark R","Dumkow, Lisa E"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339304","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/phar.2410","keywords":["covid-19","sars-cov-2","coronavirus","corticosteroid","immunosuppression","renal transplant"],"topics":["Treatment"],"weight":1,"_version_":1665264685472022528,"score":195.24216},{"pmid":32320494,"title":"Systemic Immunosuppressive Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic.","text":["Systemic Immunosuppressive Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic.","BACKGROUND/OBJECTIVES: The COVID-19 pandemic has raised questions about the approach to management of systemic immunosuppressive therapies for dermatologic indications in children. Given the absence of data to address concerns related to SARS-CoV-2 infection while on these agents in an evidence-based manner, a Pediatric Dermatology COVID-19 Response Task Force (PDCRTF) was assembled to offer time-sensitive guidance for clinicians. METHODS: A survey was distributed to an expert panel of 37 pediatric dermatologists on the PDCRTF to assess expert opinion and current practice related to three primary domains of systemic therapy: initiation, continuation, and laboratory monitoring. RESULTS: Nearly all respondents (97%) reported that the COVID-19 pandemic had impacted their decision to initiate immunosuppressive medications. The majority of pediatric dermatologists (87%) reported that they were pausing or reducing the frequency of laboratory monitoring for certain immunosuppressive medications. In asymptomatic patients, continuing therapy was the most popular choice across all medications queried. The majority agreed that patients on immunosuppressive medications who have a household exposure to COVID-19 or test positive for acute infection should temporarily discontinue systemic and biologic medications, with the exception of systemic steroids, which may require tapering. CONCLUSIONS: The ultimate decision regarding initiation, continuation and laboratory monitoring of immunosuppressive therapy during the pandemic requires careful deliberation, consideration of the little evidence available, and discussion with families. Consideration of an individual's adherence to COVID-19 preventive measures, risk of exposure, and the potential severity if infected must be weighed against the dermatological disease, medication, and risks to the patient of tapering or discontinuing therapies.","Pediatr Dermatol","Reynolds, Sean D","Mathur, Anubhav N","Chiu, Yvonne E","Brandling-Bennett, Heather A","Pope, Elena","Siegel, Michael P","Holland, Kristen E","Paller, Amy S","Siegfried, Elaine C","Tom, Wynnis L","Lara-Corrales, Irene","Tollefson, Megha M","Maguiness, Sheilagh","Eichenfield, Lawrence F","Sugarman, Jeffrey","Frieden, Ilona J","Oza, Vikash S","Cipriano, Sarah D","Huang, Jennifer T","Shah, Sonal D","Lauren, Christine T","Castelo-Soccio, Leslie","McMahon, Patrick","Cordoro, Kelly M","32320494"],"abstract":["BACKGROUND/OBJECTIVES: The COVID-19 pandemic has raised questions about the approach to management of systemic immunosuppressive therapies for dermatologic indications in children. Given the absence of data to address concerns related to SARS-CoV-2 infection while on these agents in an evidence-based manner, a Pediatric Dermatology COVID-19 Response Task Force (PDCRTF) was assembled to offer time-sensitive guidance for clinicians. METHODS: A survey was distributed to an expert panel of 37 pediatric dermatologists on the PDCRTF to assess expert opinion and current practice related to three primary domains of systemic therapy: initiation, continuation, and laboratory monitoring. RESULTS: Nearly all respondents (97%) reported that the COVID-19 pandemic had impacted their decision to initiate immunosuppressive medications. The majority of pediatric dermatologists (87%) reported that they were pausing or reducing the frequency of laboratory monitoring for certain immunosuppressive medications. In asymptomatic patients, continuing therapy was the most popular choice across all medications queried. The majority agreed that patients on immunosuppressive medications who have a household exposure to COVID-19 or test positive for acute infection should temporarily discontinue systemic and biologic medications, with the exception of systemic steroids, which may require tapering. CONCLUSIONS: The ultimate decision regarding initiation, continuation and laboratory monitoring of immunosuppressive therapy during the pandemic requires careful deliberation, consideration of the little evidence available, and discussion with families. Consideration of an individual's adherence to COVID-19 preventive measures, risk of exposure, and the potential severity if infected must be weighed against the dermatological disease, medication, and risks to the patient of tapering or discontinuing therapies."],"journal":"Pediatr Dermatol","authors":["Reynolds, Sean D","Mathur, Anubhav N","Chiu, Yvonne E","Brandling-Bennett, Heather A","Pope, Elena","Siegel, Michael P","Holland, Kristen E","Paller, Amy S","Siegfried, Elaine C","Tom, Wynnis L","Lara-Corrales, Irene","Tollefson, Megha M","Maguiness, Sheilagh","Eichenfield, Lawrence F","Sugarman, Jeffrey","Frieden, Ilona J","Oza, Vikash S","Cipriano, Sarah D","Huang, Jennifer T","Shah, Sonal D","Lauren, Christine T","Castelo-Soccio, Leslie","McMahon, Patrick","Cordoro, Kelly M"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320494","week":"202017|Apr 20 - Apr 26","doi":"10.1111/pde.14202","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664815087855075328,"score":189.33124},{"pmid":32348042,"title":"[SARS-CoV-2 infection and solid organ transplantation].","text":["[SARS-CoV-2 infection and solid organ transplantation].","Transplantation has become a valid therapeutic option for an increasing number of patients with end-stage organ disease. The emergence of SARS-CoV-2 coronavirus infection and associated disease (COVID-19) has alarmed the transplant community, since recommendations for adequate follow-up of organ transplant recipients during the acute phase of a pandemic are limited. Furthermore, treatment options against COVID-19 disease and adequate adjustment of immunosuppression in at risk patients remain a concern. This review summarizes current knowledge on the incidence and clinical course of SARS-CoV-2 infection in patients with solid organ transplantation. It also discusses therapeutic strategies and provides general recommendations on how to proceed with transplantation programs in a time when health care resources may become scarce.","Rev Med Suisse","Golshayan, Dela","Aubert, John-David","Hullin, Roger","Moradpour, Darius","Venetz, Jean-Pierre","Manuel, Oriol","Pascual, Manuel","32348042"],"abstract":["Transplantation has become a valid therapeutic option for an increasing number of patients with end-stage organ disease. The emergence of SARS-CoV-2 coronavirus infection and associated disease (COVID-19) has alarmed the transplant community, since recommendations for adequate follow-up of organ transplant recipients during the acute phase of a pandemic are limited. Furthermore, treatment options against COVID-19 disease and adequate adjustment of immunosuppression in at risk patients remain a concern. This review summarizes current knowledge on the incidence and clinical course of SARS-CoV-2 infection in patients with solid organ transplantation. It also discusses therapeutic strategies and provides general recommendations on how to proceed with transplantation programs in a time when health care resources may become scarce."],"journal":"Rev Med Suisse","authors":["Golshayan, Dela","Aubert, John-David","Hullin, Roger","Moradpour, Darius","Venetz, Jean-Pierre","Manuel, Oriol","Pascual, Manuel"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348042","source":"PubMed","week":"202018|Apr 27 - May 03","topics":["Treatment","Prevention"],"weight":1,"_version_":1665441658246791169,"score":188.99168}]}